NurExone Biologic's Q3 Loss Widens; to Submit IND Application With FDA For ExoPTEN by Q4'24
NurExone Biologic's Q3 Loss Widens; to Submit IND Application With FDA For ExoPTEN by Q4'24
NurexOne Biologic第三季度虧損擴大;將在24年第四季度之前向美國食品藥品管理局提交Exopten的IND申請
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊